Bionary Bioproducts

www.bionarybio.com

Bionary Bioproducts is a product based biotechnology company. We are into development of metabolites from microbial sources. We are presently developing process for production of amino acids, peptides, enzymes etc.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

PR Newswire | August 26, 2020

news image

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More

Industry Outlook

TRILINK BIOTECHNOLOGIES INTRODUCES LATEST MRNA CAPPING TECHNOLOGY: CLEANCAP® M6 ANALOG

Globenewswire | May 15, 2023

news image

TriLink BioTechnologies a Maravai LifeSciences company and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6 . The latest CleanCap analog is expected to help developers and researchers maximize the impact of their mRNA therapeutics and vaccines while reducing overall manufacturing costs, bringing life-changing medicines to market faster. With the introduction of the CleanCap M6 technology, legacy capping methods like enzy...

Read More

Medical

AMBAGON THERAPEUTICS LAUNCHES WITH $85 MILLION SERIES A TO ADVANCE PIONEERING MOLECULAR GLUE PLATFORM AND PROGRESS PIPELINE

Ambagon Therapeutics | January 07, 2022

news image

Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. Ambagon was previously seeded by RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital. Investors from the seed round joined th...

Read More

Medical

BLUEROCK THERAPEUTICS AND BIT.BIO ANNOUNCE COLLABORATION AND OPTION AGREEMENT FOR THE DISCOVERY AND MANUFACTURE

PRNewswire | August 04, 2023

news image

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics. "Tregs play a crucial role in maintaining balance in the body's immune system and controlling excessive immune reactions...

Read More
news image

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

PR Newswire | August 26, 2020

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More
news image

Industry Outlook

TRILINK BIOTECHNOLOGIES INTRODUCES LATEST MRNA CAPPING TECHNOLOGY: CLEANCAP® M6 ANALOG

Globenewswire | May 15, 2023

TriLink BioTechnologies a Maravai LifeSciences company and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6 . The latest CleanCap analog is expected to help developers and researchers maximize the impact of their mRNA therapeutics and vaccines while reducing overall manufacturing costs, bringing life-changing medicines to market faster. With the introduction of the CleanCap M6 technology, legacy capping methods like enzy...

Read More
news image

Medical

AMBAGON THERAPEUTICS LAUNCHES WITH $85 MILLION SERIES A TO ADVANCE PIONEERING MOLECULAR GLUE PLATFORM AND PROGRESS PIPELINE

Ambagon Therapeutics | January 07, 2022

Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. Ambagon was previously seeded by RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital. Investors from the seed round joined th...

Read More
news image

Medical

BLUEROCK THERAPEUTICS AND BIT.BIO ANNOUNCE COLLABORATION AND OPTION AGREEMENT FOR THE DISCOVERY AND MANUFACTURE

PRNewswire | August 04, 2023

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics. "Tregs play a crucial role in maintaining balance in the body's immune system and controlling excessive immune reactions...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us